BUZZ-Ionis Pharma rises as FDA approves genetic disorder drug

Reuters12-20

** Shares of drugmaker Ionis Pharmaceuticals IONS.O rise ~8% to $38.43 premarket

** On Thursday, IONS said the U.S. FDA approved co's genetic disorder drug, olezarsen, to treat familial chylomicronemia syndrome (FCS)

** FCS is a condition that prevents the body from breaking down fats and is characterized by extremely high levels of triglycerides

** Brokerage TD Cowen forecasts peak sales of $82 mln in FY32 for FCS market

** 17 of 25 brokerages rate the stock "buy" or higher, 7 "hold" and 1 "sell"; their median PT is $62 - LSEG

** As of last close, stock has fallen 29.7% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492041143?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 19:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492041143","market":"us","top_or_hot":-1,"title":"BUZZ-Ionis Pharma rises as FDA approves genetic disorder drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Ionis Pharma rises as FDA approves genetic disorder drug</title></head><body><p>** Shares of drugmaker Ionis Pharmaceuticals <span>IONS.O</span> rise ~8% to $38.43 premarket</p><p>** On Thursday, IONS said the U.S. FDA <span>approved</span> co's genetic disorder drug, olezarsen, to treat familial chylomicronemia syndrome (FCS)</p><p>** FCS is a condition that prevents the body from breaking down fats and is characterized by extremely high levels of triglycerides</p><p>** Brokerage TD Cowen forecasts peak sales of $82 mln in FY32 for FCS market</p><p>** 17 of 25 brokerages rate the stock \"buy\" or higher, 7 \"hold\" and 1 \"sell\"; their median PT is $62 - LSEG</p><p>** As of last close, stock has fallen 29.7% YTD</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal<a href=\"https://laohu8.com/S/02403\">.C</a>houdhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Ionis Pharma rises as FDA approves genetic disorder drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Ionis Pharma rises as FDA approves genetic disorder drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 19:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nL4N3NL0LH:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BUZZ-Ionis Pharma rises as FDA approves genetic disorder drug** Shares of drugmaker Ionis Pharmaceuticals IONS.O rise ~8% to $38.43 premarket** On Thursday, IONS said the U.S. FDA approved co's ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nL4N3NL0LH:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241220:nL4N3NL0LH:1","article_id":"2492041143","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492041143","pubTimestamp":1734695648,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Ionis Pharma rises as FDA approves genetic disorder drug** Shares of drugmaker Ionis Pharmaceuticals IONS.O rise ~8% to $38.43 premarket** On Thursday, IONS said the U.S. FDA approved co's genetic disorder drug, olezarsen, to treat familial chylomicronemia syndrome ** FCS is a condition that prevents the body from breaking down fats and is characterized by extremely high levels of triglycerides** Brokerage TD Cowen forecasts peak sales of $82 mln in FY32 for FCS market** 17 of 25 brokerages rate the stock \"buy\" or higher, 7 \"hold\" and 1 \"sell\"; their median PT is $62 - LSEG** As of last close, stock has fallen 29.7% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"FDA批准遗传疾病药物，BUZZ-Ionis Pharma股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":0.9},"content_text":"BUZZ-Ionis Pharma rises as FDA approves genetic disorder drug** Shares of drugmaker Ionis Pharmaceuticals IONS.O rise ~8% to $38.43 premarket** On Thursday, IONS said the U.S. FDA approved co's genetic disorder drug, olezarsen, to treat familial chylomicronemia syndrome (FCS)** FCS is a condition that prevents the body from breaking down fats and is characterized by extremely high levels of triglycerides** Brokerage TD Cowen forecasts peak sales of $82 mln in FY32 for FCS market** 17 of 25 brokerages rate the stock \"buy\" or higher, 7 \"hold\" and 1 \"sell\"; their median PT is $62 - LSEG** As of last close, stock has fallen 29.7% YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492041143"}